Chemotherapy of neoplastic disease with folate antagonists.
D000208:Acute Disease; D000284:Administration, Oral; D000328:Adult; D000367:Age Factors; D001835:Body Weight; D002051:Burkitt Lymphoma / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000532:radiotherapy; D002648:Child; D002822:Choriocarcinoma / Q000188:drug therapy; D004338:Drug Combinations; D005260:Female; D005493:Folic Acid Antagonists / Q000008:administration & dosage*; D006801:Humans; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D007938:Leukemia / Q000188:drug therapy; D015122:Mercaptopurine / Q000008:administration & dosage; D008727:Methotrexate / Q000008:administration & dosage / Q000633:toxicity; D011241:Prednisone / Q000008:administration & dosage; D011247:Pregnancy; D013997:Time Factors; D014750:Vincristine / Q000008:administration & dosage
D004338:Drug Combinations; D005493:Folic Acid Antagonists; D014750:Vincristine; D015122:Mercaptopurine; D011241:Prednisone; D008727:Methotrexate